Information Provided By: 
Fly News Breaks for September 30, 2015
OPHT
Sep 30, 2015 | 09:19 EDT
Noting that Ophthotech's stock has tumbled 30% over the past three months, Oppenheimer continues to believe that the company's Fovista program carries little risk following positive Phase II data. The firm says that Fovista is well-positioned in the $7B wet AMD market. It keeps a $95 price target and Outperform rating.
News For OPHT From the Last 2 Days
There are no results for your query OPHT
